Results 11 to 20 of about 77,778 (298)

Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged < 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025

Eurosurveillance
We measured effectiveness of nirsevimab against laboratory-confirmed respiratory syncytial virus (RSV) infection in a test-negative case-control study among children aged 
VEBIS hospital network RSV IE group
doaj   +2 more sources

Global molecular diversity of RSV – the “INFORM RSV” study [PDF]

BMC Infectious Diseases, 2020
Abstract Background Respiratory syncytial virus (RSV) is a global cause of severe respiratory morbidity and mortality in infants. While preventive and therapeutic interventions are being developed, including antivirals, vaccines and monoclonal antibodies, little is known about the global molecular epidemiology of RSV.
Langedijk, Annefleur C., Lebbink, Robert Jan, Naaktgeboren, Christiana, Evers, Anouk, Viveen, Marco C., Greenough, Anne, Heikkinen, Terho, Stein, Renato T., Richmond, Peter, Martinón-Torres, Federico, Nunes, Marta, Hosoya, Mitsuaki, Keller, Christian, Bauck, Monika, Cohen, Robert, Papenburg, Jesse, Pernica, Jeffrey, Hennus, Marije P., Jin, Hong, Tabor, David E., Tovchigrechko, Andrev, Ruzin, Alexey, Abram, Michael E., Wilkins, Deidre, Wildenbeest, Joanne G., Kragten-Tabatabaie, Leyla, Coenjaerts, Frank E J, Esser, Mark T., Bont, Louis J.   +28 more
  +11 more sources

The path to an RSV vaccine [PDF]

Current Opinion in Virology, 2013
Respiratory syncytial virus (RSV) is the greatest remaining unmet infant vaccine need in developed countries and an important unmet infant vaccine need worldwide. More than 40 years of effort have yet to result in a licensed RSV vaccine for humans.
Christine A, Shaw, Max, Ciarlet, Brian W, Cooper, Lamberto, Dionigi, Paula, Keith, Karen B, O'Brien, Maryam, Rafie-Kolpin, Philip R, Dormitzer   +7 more
openaire   +2 more sources

Role and Virology of RSV and RSV RNA Polymerase

The FASEB Journal, 2021
Respiratory syncytial virus (RSV) is a highly contagious, respiratory virus that commonly infects children under the age of five. RSV infections can present as cold‐like symptoms which include a runny nose, coughing, and fever among other common symptoms; however, RSV can cause more severe infections such as bronchiolitis and ...
Tina Link, Lan Nguyen, Avary Andrews, Joseph Fisher, Abhishek Kona, Aryn Wright   +5 more
openaire   +1 more source

An outbreak of RSV infections in a neonatology clinic during the RSV-season [PDF]

BMC Pediatrics, 2021
Abstract Background Respiratory syncytial virus (RSV) is the predominant cause of lower respiratory tract infections (LRTI) in infancy. Preterm infants with bronchopulmonary dysplasia (BPD) are at the highest risk of severe RSV-LRTI.
Liliya Vakrilova, Stanislava Hitrova Nikolova, Sergei Slavov, Petya Radulova, Boryana Slancheva   +4 more
openaire   +3 more sources

SARS-CoV-2 Vaccines: A Brief Review

Pediatric Respirology and Critical Care Medicine, 2020
SARS-CoV-2 has immensely changed the landscape in how vaccines are researched and developed. The timeline truncated for the propose of meeting the grave demand. Children stand to benefit from herd immunity for multiple reasons. Protection from SARS-CoV-2
Brandon Chatani, Daniel K. Ng
doaj   +1 more source

Molecular Detection of Upper Respiratory Tract Viral Infection with RSV, HPIV & Adenovirus among SARS-CoV2 Negative patients with respiratory illness admitted in tertiary care hospital in Eastern India

Archives of Pharmaceutical Sciences Ain Shams University, 2023
Background: The most prevalent disease-causing agents in humans are respiratory viruses, which have a global influence on morbidity and death. The Adenovirus, respiratory syncytial virus (RSV), and parainfluenza viruses (HPIV) are the dominant ...
Nivedita Mukherjee , Swati Nayek, Sanjoy Mondal, Tanusri Biswas, Arghya Nath   +4 more
doaj   +1 more source

Timing of monoclonal antibody for seasonal RSV prophylaxis in the United Kingdom. [PDF]

, 2006
Respiratory syncytial virus (RSV) infection produces more severe disease and increased hospitalization rates in high-risk babies. The monoclonal antibody palivizumab offers protection against complications, and the first of five monthly doses should be ...
Nguyen-Van-Tam, JS, M. C. Cooke, J. S. Nguyen-van-tam, R. K. Gupta, Gupta, RK, Goddard, NL, N. L. Goddard, Cooke, MC   +7 more
core   +1 more source

RSV awareness, risk perception, causes, and terms: Perspectives of pregnant and lactating women in Kenya to inform demand generation efforts for maternal RSV vaccines

Human Vaccines & Immunotherapeutics, 2023
Respiratory syncytial virus (RSV) causes a substantial proportion of acute lower respiratory tract infections (LRTI) among infants. In low- and middle-income countries, RSV may be responsible for approximately 40% of all hospital admissions of infants ...
Rupali J. Limaye, Berhaun Fesshaye, Prachi Singh, Ruth A. Karron   +3 more
doaj   +1 more source

The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya [PDF]

, 2009
Background Respiratory syncytial virus (RSV) is the major cause of lower respiratory tract infection in infants. The rate of decay of RSV-specific maternal antibodies (RSV-matAb), the factors affecting cord blood levels, and the relationship between ...
Nokes D. James, Ochola Rachel, Cane Patricia A., Scott, P. D. (Paul D.), Charles Sande, Medley Graham F., Fegan, Gregory, Scott, Paul D, Rachel Ochola, Greg Fegan, Cane, Patricia, Scott Paul D., Cane, Patricia A, Nokes, D. James, Paul D Scott, Sande Charles, Sande, Charles, Fegan Gregory, Medley, Graham F, Patricia A Cane, Fegan, Greg, D James Nokes, Ochola, Rachel, Medley, Graham, Graham F Medley, Nokes, D James, Gregory Fegan   +26 more
core   +1 more source